The role of surface functionalization in the design of PLGA micro- and nanoparticles

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 27, Issue 1, 2010, Pages 1-83

  Ratzinger, Gerda ^a   Fillafer, Christian ^a   Kerleta, Vera ^a   Wirth, Michael ^a   Gabor, Franz ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Microparticles; Nanoparticles; PLGA; Surface modification; Targeting

Indexed keywords

AMPHOPHILE; ANTISENSE OLIGONUCLEOTIDE; BIOTIN; CARBOXYLIC ACID; CHITOSAN; COBALAMIN; DIETHYLAMINOETHYLDEXTRAN; DOCETAXEL; DOXORUBICIN; EMULSIFYING AGENT; EUDRAGIT; FLUORESCENT DYE; GELATIN; HETASTARCH; LOPERAMIDE; MACROGOL; MICROSPHERE; NANOPARTICLE; PHOSPHOLIPID; PLASMID DNA; POLOXAMER; POLYAMIDOAMINE; POLYETHYLENEIMINE; POLYGLACTIN; POLYLYSINE; POLYMER; PROTAMINE; PROTAMINE SULFATE; THIAMINE; UNINDEXED DRUG;

ADSORPTION; ANALYTIC METHOD; ANTIGEN PRESENTING CELL; ATOMIC FORCE MICROSCOPY; CELL ADHESION; CELL MIGRATION; CELL SURFACE; CHEMICAL INTERACTION; CHEMICAL MODIFICATION; CIRCULATION; COVALENT BOND; DENDRITIC CELL; DIFFUSION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DESIGN; EMULSION; EVAPORATION; HYDROPHILICITY; HYDROPHOBICITY; IONIC STRENGTH; ISOTOPE LABELING; MACROMOLECULE; MACROPHAGE; MOLECULAR WEIGHT; NONHUMAN; PARTICLE SIZE; PH; PRECIPITATION; REVIEW; SPRAY DRYING; SURFACE CHARGE; SURFACE PROPERTY;

EID: 77952484431     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v27.i1.10     Document Type: Review

References (320)

1. Scopus.com [database on the Internet]. Amsterdam: Elsevier B.V.; 2009 [cited 2009 Aug 4]. Available from: http://www.scopus.com/home.url.
2. Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst. 1995;12(1):1-99.
3. Gilding DK, Reed AM. Biodegradable polymers for use in surgery: polyglycolic/poly(lactic acid) homo- and copolymers. 1. Polymer. 1979;20:137-143
4. Dorta MJ, Manguia O, Llabres M. Effects of polymerization variables on PLGA properties: molecular weight, composition and chain structure. Int J Pharm. 1993;100:9-14.
5. Neal JC, Stolnik S, Schacht E, Kenawy ER, Garnett MC, Davis SS, Illum L. In vitro displacement by rat serum of adsorbed radiolabeled poloxamer and poloxamine copolymers from model and biodegradable nanospheres. J Pharm Sci. 1998;87(10):1242-1248
6. Huang N-P, Michel R, Voros J, Textor M, Hofer R, Rossi A, Elbert DL, Hubbell JA, Spencer ND. Poly(l-lysine)-g-poly(ethylene glycol) layers on metal oxide surfaces: Surface-analytical characterization and resistance to serum and fibrinogen adsorption. Langmuir. 2001;17(2):489-498
7. Faraasen S, Voros J, Csucs G, Textor M, Merkle HP, Walter E. Ligandspecific targeting of microspheres to phagocytes by surface modification with poly(L-lysine)-grafted poly(ethylene glycol) conjugate. Pharm Res. 2003;20(2):237-246
8. Hermann J, Bodmeier R. Biodegradable, somatostatin acetate containing microspheres prepared by various aqueous and non-aqueous solvent evaporation methods. Eur J Pharm Biopharm. 1998;45:72-85.
9. Rafler G, Jobmann M. Controlled release systems of biodegradable polymers: 5th communication--microparticle preparation by a salting out process. Pharm Ind. 1997;59:620-627
10. Pavanetto F, Genta I, Giunchedi P, Conti P. Evaluation of spray-drying as a method for polylactide and polylactide-co-glycolide microsphere preparation. J Microencaps. 1993;10:487-497
11. Johansen P, Merkle HP, Gander B. Technological considerations related to up-scaling of protein microencapsulation by spray-drying. Eur J Pharm Biopharm. 2000;50:413-417
12. Herbert P, Murphy K, Johnson O, Dong N, Jaworowicz W, Tracy MA, Cleland JL, Putney SD. A large-scale process to produce microencapsulated proteins. Pharm Res. 1998;15:357-362
13. Lecaroz C, Gamazo C, Renedo MJ, Blanco-Prieto MJ. Biodegradable micro- and nanoparticles as long-term delivery vehicles for gentamycin. J Microencaps. 2006;23:782-792
14. Corrigan OI, Li X. Quantifying drug release from PLGA nanoparticulates, Eur J Pharm Sci. 2009;37:477-485
15. Govender T, Stolnik S, Garnett MC, Illum L, Davis SS. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release. 1999;57:171-185
16. Bilati U, Allemann E, Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci. 2005;24:67-75.
17. Mehta AK, Yadav KS, Sawant KK. Nimodipine loaded PLGA nanoparticles: Formulation optimisation using factorial design, characterization and in vitro evaluation. Curr Drug Deliv. 2007;4:185-193
18. Bala I, Hariharan S, Kumar R. PLGA-nanoparticles in drug delivery: The state of the art. Crit Rev Ther Drug Carrier Syst. 2004;21: 387-422.
19. Freitas S, Merkle HP, Gander B. Microencapsulation by solvent extraction/ evaporation: reviewing the state of the art of microsphere preparation process technology. J Control Release. 2005;102:313-332
20. Astete CE, Sabliov CM. Synthesis and characterisation of PLGA nanoparticles. J Biomater Sci Polym Ed. 2006;17:247-289
21. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives. J Control Release. 2008;125(3):193-209
22. Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm. 2008;364: 298-327.
23. Brannon-Peppas L, Vert M. Polylactic and polyglycolic acid as drug delivery carriers. In: Wise DL, ed. Handbook of pharmaceutical controlled release technology. New York: Marcel Dekker, 2000.
24. Perrin DA, English JP. Polyglycolide and polylactide. In: Domb AJ, Kost J, Wiseman DM, eds. Handbook of biodegradable polymers. Amsterdam: Harwood Academic Publishers, 1997.
25. Spenlehauer G, Vert M, Benoit JP, Boddaert A. In vitro and in vivo degradation of poly(D,L-lactide/glycolide) type microspheres made by solvent evaporation method. Biomaterials. 1989;10:557-563
26. Kang J, Schwendeman SP. Pore closing and opening in biodegradable polymers and their effect on the controlled release of proteins. Mol Pharm. 2007;4:104-118
27. Makino K, Mogi T, Ohtake N, Yoshida M, Ando S, Nakajima T, Ohshima H. Pulsatile drug release from poly (lactide-co-glycolide) microspheres: How does the composition of the polymer matrices affect the time interval between the initial burst and the pulsatile release of drugs? Colloids Surf B Biointerfaces. 2000;19:173-179
28. Cai Q, Shi GX, Bei JZ, Wang SG. Enzymatic degradation behaviour and mechanism of poly(lactide-co-glycolide) foams by trypsin. Biomaterials. 2003;24:629-638
29. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28:5-24.
30. Avgoustakis K, Nixon JR. Biodegradable controlled release tablets: III. Effect of polymer characteristics on drug release from heterogeneous poly(lactide-co-glycolide) matrices. Int J Pharm. 1993;99:247-252
31. Hua N, Sun J. Body distribution of poly(D,L-lactide-co-glycolide) copolymer degradation products in rats. J Mater Sci Mater Med. 2008;19:3243-3248
32. Kohane DS, Tse JY, Yeo Y, Padera R, Shubina M, Langer R. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. J Biomed Mat Res. 2006;77:351-361
33. Cenni E, Granchi D, Avnet S, Fotia C, Salerno M, Micieli D, Sarpietro MG, Pignatello R, Castelli F, Baldini N. Biocompatibility of poly(D,Llactide- co-glycolide) nanoparticles conjugated with alendronate. Biomaterials. 2008;29:1400-1411
34. Kim D, El-Shall H, Dennis D, Morey T. Interaction of PLGA nanoparticles with human blood constituents. Colloids Surf B Biointerfaces. 2005;40:83-91.
35. Ignatius AA, Claes LE, In vitro biocompatibility of bioresorbable polymers: poly(L,DL-lactide) and poly(L-lactide-co-glycolide). Biomaterials. 1996;17:831-839
36. Malyala P, OHagan DT, Singh M. Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable particles. Adv Drug Deliv Rev. 2009;61:218-225
37. Wendorf J, Singh M, Chesko J, Kazzaz J, Soewanan E, Ugozzoli M, OHagan D. A practical approach to the use of nanoparticles for vaccine delivery. J Pharm Sci. 2006;95:2738-2750
38. Hermanson GT. Bioconjugate techniques. San Diego: Academic Press, 1996.
39. Kasturi PS, Qin H, Thomson KS, El-Bereir S, Cha S-C, Neelapu S, Kwak LW, Roy K. Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethyleneimine (PEI) functionalized PLGA microparticles. J Control Release. 2006;113(3):261-270
40. Gabor F, Trimmel K, Ratzinger G, Kerleta V, Fillafer C, Wirth M. Characterization of binding and uptake of biomimetic nanoparticles by flow cytometry. J Drug Delivery Sci Technol. 2008;18(1):51-57
41. Chen H, Gao J, Lu Y, Kou G, Zhang H, Fan L, Sun Z, Guo Y, Zhong Y. Preparation and characterization of PE38KDEL-loaded anti- HER2 nanoparticles for targeted cancer therapy. J Control Release. 2008;128:209-216
42. Brandhonneur N, Chevanne F, Vie V, Frisch B, Primault R, Le Poitier M-F, Le Corre P. Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages. Eur J Pharm Sci. 2009;36:474-485
43. Sharon JL, Puleo DA. The use of N-terminal immobilization of PTH(1- 34) on PLGA to enhance bioactivity. Biomaterials. 2008;29:3137-3142
44. McCarron PA, Marouf WM, Donnelly RF, Scott C. Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polymeric acid functionality. J Biomed Mater Res. 2008;87:873-884
45. Ratzinger G, Lnger U, Neutsch L, Pittner F, Wirth M, Gabor F. Surface modification of PLGA particles: The interplay between stabilizer, ligand size, and hydrophobic interactions. Langmuir. 2010;26(3):1855-1859.
46. Dahlgren MAG. Effect of counterion valency and ionic strength on polyelectrolyte adsorption. Langmuir. 1994;10(5):1580-1583
47. Trimaille T, Pichot C, Delair T. Surface functionalization of poly(D,Llactic acid) nanoparticles with poly(ethylenimine) and plasmid DNA by the layer-by-layer approach. Colloids Surf A Physicochem Eng Asp. 2003;221:39-48.
48. Messai I, Delair T. Adsorption of chitosan onto poly(D,L-lactic acid) particles: A physico-chemical investigation. Macromol Chem Phys. 2005;206(16):1665-1674
49. Vila A, Snchez A, Tobío M, Calvo P, Alonso MJ. Design of biodegradable particles for protein delivery. J Control Release. 2002;78:15-24.
50. Dillen K, Vandervoort J, Van den Mooter G, Ludwig A. Evaluation of ciprofloxacin-loaded Eudragit® RS100 or RL100/PLGA nanoparticles. Int J Pharm. 2006;314(1):72-82.
51. Thiele L, Rothen-Rutishauser B, Jilek S, Wunderli-Allenspach H, Merkle HP, Walter E. Evaluation of particle uptake in human blood monocytederived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J Control Release. 2001;76:59-71.
52. Vasir JK, Labhasetwar V. Quantification of the force of nanoparticle-cell membrane interactions and its influence on intracellular trafficking of nanoparticles. Biomaterials. 2008;29(31):4244-4252
53. Kim BS, Kim CS, Lee KM. The intracellular uptake ability of chitosancoated poly (D,L-lactide-co-glycolide) nanoparticles. Arch Pharm Res. 2008;31(8):1050-1054
54. Martínez Gómez JM, Csaba N, Fischer S, Sichelstiel A, Kndig TM, Gander B, Johansen P. Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis. J Control Release. 2008;130(2):161-167
55. Thiele L, Merkle HP, Walter E. Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharm Res. 2003;20(2):221-228 (Pubitemid 36269728)
56. Kumar MNVR, Mohapatra SS, Kong X, Jena PK, Bakowsky U, Lehr CM. Cationic poly(lactide-co-glycolide) nanoparticles as efficient in vivo gene transfection agents. J Nanosci Nanotechnol. 2004;4(8):990-994
57. Kumar MNRV, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials. 2004;25:1771-1777
58. Yamamoto H, Kuno Y, Sugimoto S, Takeuchi H, Kawashima Y. Surfacemodified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. J Control Release. 2005;102(2):373-381
59. Fischer S, Foerg C, Ellenberger S, Merkle HP, Gander B. One-step preparation of polyelectrolyte-coated PLGA microparticles and their functionalization with model ligands. J Control Release. 2006;111: 135-144
60. Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: Effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine. 2007;3(3):173-183
61. Guo C, Gemeinhart RA. Understanding the adsorption mechanism of chitosan onto poly(lactide-co-glycolide) particles. Eur J Pharm Biopharm. 2008;70(2):597-604.
62. Manca M-L, Mourtas S, Dracopoulos V, Fadda AM, Antimisiaris SG. PLGA, chitosan or chitosan-coated PLGA microparticles for alveolar delivery?: A comparative study of particle stability during nebulization. Colloids Surf B Biointerfaces. 2008;62(2):220-231
63. Yang R, Shim W-S, Cui F-D, Cheng G, Han X, Jin Q-R, Kim D-D, Chung S-J, Shim C-K. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int J Pharm. 2009;371(1-2):142-147
64. Yang R, Yang SG, Shim WS, Cui F, Cheng G, Kim IW, Kim DD, Chung SJ, Shim CK. Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates. J Pharm Sci. 2009;98(3):970-984
65. Tsung MJ, Burgess DJ. Preparation and characterization of gelatin surface modified PLGA microspheres. AAPS PharmSci. 2001;3(2):E11.
66. Wischke C, Zimmermann J, Wessinger B, Schendler A, Borchert HH, Peters JH, Nesselhut T, Lorenzen DR. Poly(I:C) coated PLGA microparticles induce dendritic cell maturation. Int J Pharm. 2009;365(1-2): 61-68
67. Bivas-Benita M, Romeijn S, Junginger HE, Borchard G. PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium. Eur J Pharm Biopharm. 2004;58(1):1-6.
68. Mandal B, Kempf M, Merkle HP, Walter E. Immobilisation of GM-CSF onto particulate vaccine carrier systems. Int J Pharm. 2004;269(1): 259-265
69. Oster CG, Kim N, Grode L, Barbu-Tudoran L, Schaper AK, Kaufmann SHE, Kissel T. Cationic microparticles consisting of poly(lactide-coglycolide) and polyethylenimine as carriers systems for parental DNA vaccination. J Control Release. 2005;104(2):359-377
70. Kasturi SP, Sachaphibulkij K, Roy K. Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines. Biomaterials. 2005;26:6375-6385
71. Yang YW, Hsu PYJ. The effect of poly(d,l-lactide-co-glycolide) microparticles with polyelectrolyte self-assembled multilayer surfaces on the cross-presentation of exogenous antigens. Biomaterials. 2008;29(16):2516-2526
72. Cui C, Schwendeman SP. Surface entrapment of polylysine in biodegradable poly(DL-lactide-co-glycolide) microparticles. Macromolecules. 2001;34:8426-8433
73. Mller M, Voros J, Csucs G, Walter E, Danuser G, Merkle HP, Spencer ND, Textor M. Surface modification of PLGA microspheres. J Biomed Mater Res A. 2003;66(1):55-61.
74. Kim SH, Jeong JH, Chun KW, Park TG. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)- folate conjugate. Langmuir. 2005;21:8852-8857
75. Reynolds F, Weissleder R, Josephson L. Protamine as an efficient membrane- translocating peptide. Bioconjug Chem. 2005;16(5):1240-1245
76. Boussif O, Lezoualch F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine. Proc Natl Acad Sci USA. 1995;92(16):7297-7301
77. Kircheis R, Wightman L, Wagner E. Design and gene delivery activity of modified polyethylenimines. Adv Drug Deliv Rev. 2001;53(3):341-358
78. Neu M, Fischer D, Kissel T. Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives. J Gene Med. 2005;7(8):992-1009.
79. Shakweh M, Besnard M, Nicolas V, Fattal E. Poly (lactide-co-glycolide) particles of different physicochemical properties and their uptake by peyers patches in mice. Eur J Pharm Biopharm. 2005;61(1-2): 1-13.
80. Kim I-S, Lee S-K, Park Y-M, Lee Y-B, Shin S-C, Lee KC, Oh I-J. Physicochemical characterization of poly(l-lactic acid) and poly(d,l-lactide- coglycolide) nanoparticles with polyethylenimine as gene delivery carrier. Int J Pharm. 2005;298(1):255-262
81. Arnold LJ, Dagan A, Gutheil J, Kaplan NO. Antineoplastic activity of poly(L-lysine) with some ascites tumor cells. Proc Natl Acad Sci U S A. 1979;76(7):3246-3250
82. Kou G, Gao J, Wang H, Chen H, Li B, Zhang D, Wang S, Hou S, Qian W, Dai J, Zhong Y, Guo Y. Preparation and characterization of paclitaxel-loaded PLGA nanoparticles coated with cationic SM5-1 single-chain antibody. J Biochem Mol Biol. 2007;40(5):731-739
83. Dunn SE, Coombes AGA, Garnett MC, Davis SS, Davies MC, Illum M. In vitro cell interaction and in vivo biodistribution of poly(lactide-coglycolide) nanospheres surface modified by poloxamer and poloxamine copolymers. J Control Release. 1997;44:65-76.
84. Scholes PD, Coombes AG, Illum L, Davis SS, Watts JF, Ustariz C, Vert M, Davies MC. Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable nanospheres using SSIMS and XPS. J Control Release. 1999;59(3):261-278
85. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D,L.lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release. 2002;82:105-114
86. Rojas OJ, Ernstsson M, Neuman RD, Claesson PM. Effect of polyelectrolyte charge density on the adsorption and desorption behavior on mica. Langmuir. 2002;18(5):1604-1612
87. Kim C-J. Advanced pharmaceutics: physicochemical principles. 1st ed. Boca Raton, FL: CRC Press, 2004.
88. Israelachvili J. Intramolecular and surface forces. 2nd ed. London: Academic Press,1991.
89. Evans DF, Wennerstrm H. The colloidal domain: where physics, chemistry, biology, and technology meet. 2nd ed. Hoboken, NJ: Wiley- VCH, 1999.
90. Lacasse FX, Filion MC, Phillips NC, Escher E, McMullen JN, Hildgen P. Influence of surface properties at biodegradable microsphere surfaces: Effects on plasma proteins adsorption and phagocytosis. Pharm Res. 1998;15:312-317
91. DeMerlis CC, Schoneker DR. Review of the oral toxicity of polyvinyl alcohol (PVA). Food Chem Toxicol. 2003;41:319-326
92. Patel AR, Kulkarni S, Nandekar TD, Vavia PR. Evaluation of alkyl polyglucoside as an alternative surfactant in the preparation of peptideloaded nanoparticles. J Microencaps. 2008;25(8):531-540
93. Agents reviewed by the IARC monographs. Geneva: World Health Organization, International Agency for Research on Cancer, 2009. Available from: http://monographs.iarc.fr/ENG/Classification/Listagentsalphorder. pdf.
94. Inactive Ingredient Search for Approved Drug Products (online database). Silver Spring: US Food and Drug Administration. Available from: http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm.
95. Santander-Ortega MJ, Jodar-Reyes AB, Csaba N, Bastos-Gonzalez D, Ortega-Vinuesa JL. Colloidal stability of Pluronic F68-coated PLGA nanoparticles: A variety of stabilization mechanisms. J Colloid Interface Sci. 2006;302:522-529
96. Besheer A, Vogel J, Glanz D, Kressler J, Groth T, Mder K. Characterization of PLGA nanospheres stabilized with amphiphilic polymers: hydrophobically modified hydroxyethyl starch vs Pluronics. Mol Pharm. 2009;6(2):407-415
97. Chang J, Jallouli Y, Kroubi M, Yuan X-B, Feng W, Kang C-S, Pu P-Y, Betbeder D. Characterization of endocytosis of transferrincoated PLGA nanoparticles by the blood-brain barrier. Int J Pharm. 2009;379(2):285-292
98. Singh M, Briones M, Ott G, OHagan D. Cationic microparticles: A potent delivery system for DNA vaccines. Proc Natl Acad Sci U S A. 2000;97(2):811-816
99. Otten GR, Schaefer M, Doe B, Liu H, Srivastava I, Megede J, Kazzaz J, Lian Y, Singh M, Ugozzoli M, Montefiori D, Lewis M, Driver DA, Dubensky T, Polo JM, Donnelly J, OHagan DT, Barnett S, Ulmer JB. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a primingboosting regimen with recombinant proteins. J Virol. 2005;79(13): 8189-8200
100. Kazzaz J, Neidleman J, Singh M, Ott G, OHagan DT. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J Control Release. 2000;67:347-356
101. Singh M, Kazzaz J, Chesko J, Soenawan E, Ugozzoli M, Giuliani M, Pizza M, Rappouli R, OHagan DT. Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J Pharm Sci. 2004;93(2):273-282
102. Feng S-S, Huang G. Effects of emulsifiers on the controlled release of paclitaxel (Taxol®) from nanospheres of biodegradable polymers. J Control Release. 2001;71:53-69.
103. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R. Temporal targeting of tumor cells and neovasculature with a nanoscale delivery system. Nature. 2005;436:568-572.
104. Besheer A, Hause G, Kressler J, Mder K. Hydrophobically modified hydroxyethyl starch: Synthesis, characterization, and aqueous selfassembly into nano-sized polymeric micelles and vesicles. Biomacromolecules. 2007;8:359-367
105. Mu L, Feng SS. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol®). J Control Release. 2002;80:129-144
106. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005;26:2713-2722
107. Zhao HZ, Tan EC, Yung LYL. Potential use of cholecalciferol polyethylene glycol succinate as a novel pharmaceutical additive. J Biomed Mater Res. 2008;84A:954-964
108. Laroui H, Grossin L, Leonard M, Stoltz J-F, Gillet P, Netter P, Dellacherie E. Hyaluronate-covered nanoparticles for the therapeutic targeting of cartilage. Biomacromolecules. 2007;8:3879-3885
109. Fahmy TM, Samstein RM, Harness CC, Saltzman WM. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials. 2005;26:5727-5736
110. Demento SL, Eisenbarth SC, Foellmer HG, Platt C, Caplan MJ, Saltzman WM, Mellman I, Ledizet M, Fikrig E, Flavell RA, Fahmy TM. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine. 2009;27:3013-3021
111. Cui C, Schwendeman SP. One-step surface modification of poly(lactideco- glycolide) microparticles with heparin. Pharm Res. 2007;24(12): 2381-2393
112. Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol®): PLGA nanoparticles containing vitamin E TPGS. J Control Release. 2003;86:33-48.
113. Montisci M.-J., Giovannuci G, Duchene D, Ponchel G. Covalent coupling of asparagus pea and tomato lectins to poly(lactide) microspheres. Int J Pharm. 2001;215:153-161
114. Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrin- conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm. 2005;2(5):373-383
115. Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials. 2008;29:4429-4438
116. Lu J, Jackson JK, Gleave ME, Burt HM. The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors. Cancer Chemother Pharmacol. 2008;61(6):997-1005.
117. Keegan ME, Falcone JL, Leung TC, Saltzman WM. Biodegradable microspheres with enhanced capacity for covalently bound surface ligands. Macromolecules. 2004;37:9779-9784
118. Chittasupho C, Xie S-X, Baoum A, Yakovleva T, Siahaan TJ, Berkland CJ. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur J Pharm Sci. 2009;37(2):141-150.
119. Cui C, Stevens VC, Schwendeman SP. Injectable polymer microsperes enhance immunogenicity of a contraceptive peptide vaccine. Vaccine. 2007;25:500-509
120. Chesko J, Kazzaz J, Ugozzoli M, OHagan DT, Singh M. An investigation of the factors controlling the adsorption of protein antigens to anionic PLG microparticles. J Pharm Sci. 2005;94(11):2510-2519
121. Cai C, Bakowsky U, Rytting E, Schaper AK, Kissel T. Charged nanoparticles as protein delivery systems: A feasibility study using lysozyme as model protein. Eur J Pharm Biopharm. 2008;69:31-42.
122. Crotts G, Park TG. Stability and release of bovine serum albumin encapsulated within poly(D,L-lactide-co-glycolide) microparticles. J Control Release. 1997;44:123-134
123. Crotts G, Sah H, Park TG. Adsorption determines in-vitro protein release rate from biodegradable microspheres: quantitative analysis of surface area during degradation. J Control Release. 1997;47:101-111
124. Kocbek P, Obermajer N, Gegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release. 2007;120:18-26.
125. Wang J, Wang BM, Schwendeman P. Mechanistic evaluation of the glucose-induced reduction in initial burst release of octreotide acetate from poly(D,L-lactide-co-glycolide) microspheres. Biomaterials. 2004;25:1919-1927
126. Xu Q, Crossley A, Czernuszka J. Preparation and characterization of negatively charged poly(lactic-co-glycolic acid) microspheres. J Pharm Sci. 2009;98:2377-2389
127. Villari V, Micali N. Light scattering as spectroscopic tool for the study of disperse systems useful in pharmaceutical sciences. J Pharm Sci. 2008;97:1703-1730
128. Mller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47:4-12.
129. Augsten C, Kiselev MA, Gehrke R, Hause G, Mder K. A detailed analysis of biodegradable nanospheres by different techniques: a combined approach to detect particle sizes and size distributions. J Pharm Biomed Anal. 2008;47:95-102.
130. Fraunhofer W, Winter G. The use of asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics. Eur J Pharm Biopharm. 2004;58:369-383
131. Schimpf M, Caldwell K, Giddings JC. Field-flow fractionation handbook. Hoboken, NJ: Wiley-Intersceince, 2000.
132. Musyanovych A, Schmitz-Wienke J, Mailnder V, Walther P, Landsfester K. Preparation of biodegradable polymer nanoparticles by miniemulsion technique and their cell interactions. Macromol Biosci. 2008;8:127-139
133. Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: The need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008;69:1-9.
134. Perioli L, Rossi C. Phsysicochemical characterization and release mechanism of a novel prednisone biodegradable microsphere formulation. J Pharm Sci. 2008;97:303-317
135. Gaumet M, Gurny R, Delie F. Fluorescent biodegradable PLGA particles with narrow size distributions: Preparation by means of selective centrifugation. Int J Pharm. 2007;342:222-230
136. Guan XP, Quan DP, Liao KR, Wang T, Xiang P, Mai KC. Preparation and characterization of cationic chitosan-modified poly(D,L-lactide-coglycolide) copolymer nanospheres as DNA carriers. J Biomater Appl. 2008;22:353-371
137. Gvili K, Benny O, Danino D, Machluf M. Poly(D,L-lactide-co-glycolide acid) nanoparticles for DNA delivery: Waiving preparation complexity and increasing efficiency. Biopolymers. 2007;85:379-391
138. Dorati R, Patrini M, Perugini P, Pavanetto F, Stella A, Modena T, Genta I, Cont B. Surface characterization by atomic force microscopy of sterilized PLGA microspheres. J Microencapsul. 2006;23:123-133
139. Bunjes H, Unruh T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv Drug Deliv Rev. 2007;59:379-402.
140. Agnihotri SM, Ohshima H, Terada H, Tomoda K, Makino K. Electrophoretic mobility of colloidal gold particles in electrolyte solutions. Langmuir. 2009;25:4804-4807
141. Kesisoglou F, Panmai S, Wu Y. Nanosizing - Oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 2007;59:631-644
142. Shinkai M, Yanase M, Honda H, Wakabayashi T, Yoshida J, Kobayashi T. Intracellular hyperthermia for cancer using cationic liposomes: in vitro study. Jpn J Cancer Res. 1996;87:1179-1183
143. Ito A, Shinkai M, Honda H, Kobayashi T. Medical application of functionalized magnetic nanoparticles. J Biosci Bioeng. 2005;100:1-11.
144. Stolnik S, Dunn SE, Garnett MC, Davies MC, Coombes AG, Taylor DC, Irving MP, Purkiss SC, Tadros TF, Davis SS, Illum L. Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)- poly(ethylene glycol) copolymers. Pharm Res. 1994;11(12):1800-1808 (Pubitemid 24377094)
145. Lck M, Pistel KF, Li YX, Blunk T, Mller RH, Kissel T. Plasma protein adsorption on biodegradable microspheres consisting of poly(D,L-lactideco- glycolide), poly(L-lactide) or ABA triblock copolymers containing poly(oxyethylene); Influence of production method and polymer composition. J Control Release. 1998;55:107-120
146. Shakesheff KM, Evora C, Soriano I, Langer R. The adsorption of poly(vinyl alcohol) to biodegradable microparticles studied by X-ray photoelectron spectroscopy (XPS). J Colloid Interface Sci. 1996;185: 538-547
147. Gaumet M, Gurny R, Delie F. Localization and quantification of biodegradable particles in an intestinal cell model: The influence of particle size. Eur J Pharm Sci. 2009;36:465-473
148. Weiss B, Schneider M, Muys L, Taetz S, Neumann D, Schaefer UF, Lehr CM. Coupling of biotin-(poly(ethylene glycol))amine to poly(D,Llactide- co-glycolide) nanoparticles for versatile surface modification. Bioconjug Chem. 2007;18:1087-1094
149. Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Muller RH. Stealth corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces. 2000;18(3-4):301-313
150. Ha CS, Gardella JA. Surface chemistry of biodegradable polymers for drug delivery systems. Chem Rev. 2005;105:4205-4232
151. Chesko J, Kazzaz J, Ugozzoli M, Singh M, OHagan DT, Madden C, Perkins M, Patel N. Characterization of antigens adsorbed to anionic PLG microparticles by XPS and TOF-SIMS. J Pharm Sci. 2008;97:1443-1453
152. Mehrishi JN, Bauer J. Electrophoresis of cells and the biological relevance of surface charge. Electrophoresis. 2002;23(13):1984-1994
153. Thiele L, Diederichs JE, Reszka R, Merkle HP, Walter E. Competitive adsorption of serum proteins at microparticles affects phagocytosis by dendritic cells. Biomaterials. 2003;24(8):1409-1418
154. Nguyen DN, Green JJ, Chan JM, Langer R, Anderson DG. Polymeric materials for gene delivery and DNA vaccination. Adv Mater. 2009;21(8):847-867
155. Labhasetwar V, Song C, Humphrey W, Shebuski R, Levy RJ. Arterial uptake of biodegradable nanoparticles: effect of surface modifications. J Pharm Sci. 1998;87(10):1229-1234
156. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 2002;62(21):6132-6140
157. Roser M, Fischer D, Kissel T. Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur J Pharm Biopharm. 1998;46(3):255-263
158. Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2):158-171
159. Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm. 2009;71(3): 505-518
160. Ponchel G, Irache J-M. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Deliv Rev. 1998;34(2-3):191-219.
161. Kawashima Y, Yamamoto H, Takeuchi H, Kuno Y. Mucoadhesive DLlactide/ glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm Dev Technol. 2000;5(1):77-85.
162. Vandervoort J, Yoncheva K, Ludwig A. Influence of the homogenisation procedure on the physicochemical properties of PLGA nanoparticles. Chem Pharm Bull. 2004;52(11):1273-1279
163. Grabovac V, Bernkop-Schnurch A. Development and in vitro evaluation of surface modified poly(lactide-co-glycolide) nanoparticles with chitosan- 4-thiobutylamidine. Drug Dev Ind Pharm. 2007;33(7):767-774
164. Cu Y, Saltzman WM. Drug delivery: Stealth particles give mucus the slip. Nat Mater. 2009;8(1):11-13
165. Olmsted SS, Padgett JL, Yudin AI, Whaley KJ, Moench TR, Cone RA. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J. 2001;81(4):1930-1937
166. Wang YY, Lai SK, Suk JS, Pace A, Cone R, Hanes J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that slip through the human mucus barrier. Angew Chem Int Ed Engl. 2008;47(50):9726-9729
167. Lai SK, OHanlon DE, Harrold S, Man ST, Wang Y-Y, Cone R, Hanes J. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A. 2007;104(5):1482-1487
168. Cu Y, Saltzman WM. Controlled surface modification with poly(ethylene) glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol Pharm. 2008;6(1):173-181
169. Dawson M, Krauland E, Wirtz D, Hanes J. Transport of polymeric nanoparticle gene carriers in gastric mucus. Biotechnol Prog. 2004;20(3):851-857
170. Sun B, Ranganathan B, Feng S-S. Multifunctional poly(D,L-lactideco- glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by trastuzumab for targeted chemotherapy of breast cancer. Biomaterials. 2008;29(4):475-486
171. Acharya S, Dilnawaz F, Sahoo SK. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials. 2009;30:5737-5750
172. Scott CJ, Marouf WM, Quinn DJ, Buick RJ, Orr SJ, Donnelly RF, McCarron PA. Immunocolloidal targeting of the endocytotic siglec-7 receptor using peripheral attachment of siglec-7 antibodies to poly(lactide-coglycolide) nanoparticles. Pharm Res. 2008;25(1):135-146
173. McCarron PA, Marouf WM, Quinn DJ, Fay F, Burden RE, Olwill SA, Scott CJ. Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells. Bioconjug Chem. 2008;19(8):1561-1569
174. Eniola AO, Hammer DA. In vitro characterization of leukocyte mimetic for targeting therapeutics to the endothelium using two receptors. Biomaterials. 2005;26:7136-7144
175. Sharon N, Lis H. History of lectins: from hemagglutinins to biological recognition molecules. Glycobiology. 2004;14(11):53-62.
176. Diez S, Navarro G, de Ilarduya CT. In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma. J Gene Med. 2009;11(1):38-45.
177. Gabor F, Wirth M. Lectin-mediated drug delivery: Fundamentals and perspectives. STP Pharma Sciences. 2003;13:3-16.
178. Gabor F, Stangl M, Wirth M. Lectin-mediated bioadhesion: Binding characteristics of plant lectins on the enterocyte-like cell lines Caco-2, Ht-29 and HCT-8. J Control Release. 1998;55:131-142
179. Gabor F, Klausegger U, Wirth M. The interaction between wheat germ agglutinin and other plant lectins with prostate cancer cells Du-145. Int J Pharm. 2001;221:35-47.
180. Toegel S, Harrer N, Plattner VE, Unger FM, Viernstein H, Goldring MB, Gabor F, Wirth M. Lectin binding studies on C-28/I2 and T/C- 28a2 chondrocytes provide a basis for new tissue engineering and drug delivery perspectives in cartilage research. J Control Release. 2007;117(1):121-129
181. Plattner VE, Wagner M, Ratzinger G, Gabor F, Wirth M. Targeted drug delivery: Binding and uptake of plant lectins using human 5637 bladder cancer cells. Eur J Pharm Biopharm. 2008;70(2): 572-576
182. Plattner VE, Ratzinger G, Engleder ET, Gallauner S, Gabor F, Wirth M. Alteration of the glycosylation pattern of monocytic THP-1 cells and its impact on lectin-mediated drug delivery. Eur J Pharm Biopharm. 2009;73(3):324-330
183. Gabor F, Wirth M, Jurkovich B, Haberl I, Theyer G, Walcher G, Hamilton G. Lectin-mediated bioadhesion: Proteolytic stability and binding-characteristics of Wheat germ agglutinin and Solanum tuberosum lectin on Caco-2, HT-29 and human colonocytes. J Control Release. 1997;49:27-37.
184. Lochner N, Pittner F, Wirth M, Gabor F. Wheat germ agglutinin binds to the epidermal growth factor receptor of artificial Caco-2 membranes as detected by silver nanoparticle enhanced fluorescence. Pharm Res. 2003;20(5):833-839
185. Gabor F, Bogner E, Weissenboeck A, Wirth M. The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv Drug Deliv Rev. 2004;56:459-480
186. Roth-Walter F, Schll I, Untersmayr E, Ellinger A, Boltz-Nitulescu G, Scheiner O, Gabor F, Jensen-Jarolim E. Mucosal targeting of allergen-loaded microspheres by Aleuria aurantia lectin. Vaccine. 2005;23(21):2703-2710
187. Jepson MA, Clark MA, Hirst BH. M cell targeting by lectins: A strategy for mucosal vaccination and drug delivery. Adv Drug Deliv Rev. 2004;56:511-525
188. Palumbo RN, Wang C. Bacterial invasin: Structure, function, and implication for targeted oral gene delivery. Curr Drug Deliv. 2006;3(1):47-53.
189. Des Rieux A, Fievez V, Garinot M, Schneider Y-J, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Release. 2006;116(1):1-27.
190. Dawson GF, Halbert GW. The in vitro cell association of invasin coated polylactide-co-glycolide nanoparticles. Pharm Res. 2000;17(11):1420-1425
191. Townsend SA, Evrony GD, Gu FX, Schulz MP, Brown RH, Langer R. Tetanus toxin C fragment-conjugated nanoparticles for targeted drug delivery to neurons. Biomaterials. 2007;28:5176-5184 (Pubitemid 47488499)
192. Rothenfluh DA, Bermudez H, ONeil CP, Hubbell JA. Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nat Mat. 2008;7:248-254
193. Hersel U, Dahmen C, Kessler H. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials. 2003;24:4385-4415
194. Wang Z, Chui W-K, Ho PC. Design of a multifunctional PLGA nanoparticulate drug delivery system: Evaluation of its physicochemical properties and anticancer activity to malignant cancer cells. Pharm Res. 2009;26(5):1162-1171
195. Garinot M, Fievez V, Pourcelle V, Stoffelbach F, des Rieux A, Plapied L, Theate I, Freichels H, Jerome C, Marchand-Brynaert J, Schneider Y-J, Préat V. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release. 2007;120:195-204.
196. Fievez V, Plapied L, Des Rieux A, Pourcelle V, Freichels H, Wascotte V, Vanderhaeghen M-L, Jerome C, Vanderplasschen A, Marchand- Brynaert J, Schneider Y-J, Preat V. Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur J Pharm Biopharm. 2009;73:16-24.
197. Zhang N, Chittasupho C, Duangrat C, Siahaan TJ, Berkland C. PLGA nanoparticle-peptide conjugate effectively targets intercellular celladhesion molecule-1. Bioconjug Chem. 2008;19(1):145-152
198. Costantino L, Gandolfi F, Tosi G, Rivasi F, Vandelli MA, Forni F. Peptide-derivatized biodegradable nanoparticles able to cross the bloodbrain barrier. J Control Release. 2005;108:84-96.
199. Tosi G, Costantino L, Rivasi F, Ruozi B, Leo E, Vergoni AV, Tacchi R, Bertolini A, Vandelli MA, Forni F. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with loperamide and rhodamine-123. J Control Release. 2007;122(1):1-9.
200. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer therapy in vivo. Proc Natl Acad Sci U S A. 2006;103(16):6315-6320
201. Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci. 2005;94(10):2135-2146
202. Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release. 2004;96(2):273-283
203. Zhang Z, Lee SH, Feng S-S. Folate-decorated poly(lactide-co-glycolide)- vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials. 2007;28:1889-1899
204. Lockman PR, Oyewumi MO, Koziara JM, Roder KE, Mumper RJ, Allen DD. Brain uptake of thiamine-coated nanoparticles. J Control Release. 2003;93:271-282
205. Salman HH, Gamazo C, de Smidt PC, Russell-Jones G, Irache JM. Evaluation of bioadhesive capacity and immunoadjuvant properties of vitamin B(12)-Gantrez Nanoparticles. Pharm Res. 2008;25(12):2859-2868
206. Choi S-W, Kim J-H. Design of surface-modified poly(D,L-lactide- coglycolide) nanoparticles for targeted drug delivery to bone. J Control Release. 2007;122:24-30.
207. Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev. 2007;59:718-728
208. Breunig M, Bauer S, Goepferich A. Polymers and nanoparticles: intelligent tools for intracellular targeting? Eur J Pharm Biopharm. 2008;68:112-128
209. Behr J-P. The proton sponge: A trick to enter cells the viruses did not exploit. Chimia. 1997;51:34-36
210. Pack DW, Hoffmann AS, Pun S, Stayton PS. Design and development of polymers for gene delivery. Nat Rev Drug Discov. 2005;4:581-593
211. Bivas-Benita M, Lin MY, Bal SM, Meijgaarden KE, Franken KLMC, Friggen AH, Junginger HE, Borchard G, Klein MR, Ottenhoff THM. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine. 2009;27:4010-4017
212. Panyam J, Zhou W-Z, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: Implications for drug and gene delivery. FASEB J. 2002;16:1217-1226
213. Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev. 2005;57:637-651
214. Foerg C, Merkle HP. On the biomedical promise of cell penetrating peptides: Limits versus prospects. J Pharm Sci. 2008;97(1):144-162
215. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med. 2004;10(3):310-315
216. Nam YS, Park JY, Han S-H, Chang I-S. Intracellular drug delivery using poly(D,L-lactide-co-glycolide) nanoparticles derivatized with a peptide from a transcriptional activator protein of HIV-1. Biotechnol Lett. 2002;24:2093-2098
217. Lee S-J, Jeong J-R, Shin S-C, Huh Y-M, Song H-T, Suh J-S, Chang Y-H, Jeon B-S, Kim J-D. Intracellular translocation of superparamagnetic iron oxide nanoparticles with peptide-conjugated poly(D,L-lactide-coglycolide). J Appl Phys. 2005;97(10):1-3.
218. Pouton CW, Wagstaff KM, Roth DM, Moseley GW, Jans DA. Targeted delivery to the nucleus. Adv Drug Deliv Rev. 2007;59:698-717.
219. Suh J, Dawson M, Hanes J. Real-time multiple-particle tracking: applications to drug and gene delivery. Adv Drug Deliv Rev. 2005;57:63-78.
220. Ng CP, Goodman TT, Park I-K, Pun SH. Bio-mimetic surface engineering of plasmid-loaded nanoparticles for active intracellular trafficking by actin comet-tail motility. Biomaterials. 2009;30:951-958
221. Cheng F-Y, Wang SP-H, Su C-H, Tsai T-L, Wu P-C, Shieh D-B, Chen J-H, Hsieh PC-H, Yeh C-S. Stabilizer-free poly(lactide-co-glycolide) nanoparticles for multimodal biomedical probes. Biomaterials. 2008;29(13):2104-2112
222. Xu P, Gullotti E, Tong L, Highley CB, Errabelli DR, Hasan T, Cheng J-X, Kohane DS, Yeo Y. Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Mol Pharm. 2008;6(1):190-201.
223. Gruenberg J, Van der Goot FG. Mechanisms of pathogen entry through the endosomal compartments. Nat Rev Mol Cell Biol. 2006;7: 495-504.
224. Medina-Kauwe LK. Alternative endocytic mechanisms exploited by pathogens: new avenues for therapeutic delivery? Adv Drug Deliv Rev. 2007;59:798-809.
225. Wright AE, Douglas SR. An experimental investigation of the role of the blood fluids in connection with phagocytosis. Proc R Soc Lond. 1903;72:357-370
226. Patel HM. Serum opsonins and liposomes: Their interaction and opsonophagocytosis. Crit Rev Ther Drug Carrier Syst. 1992;9(1):39-90.
227. Moghimi SM, Muir IS, Illum L, Davis SS, Kolb-Bachofen V. Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim Biophys Acta. 1993;1179:157-165
228. Harashima H, Matsuo H, Kiwada H. Identification of proteins mediating clearance of liposomes using a liver perfusion system. Adv Drug Deliv Rev. 1998;32(1-2):61-79.
229. Gref R, Domb A, Quellec P, Blunk T, Mller RH, Verbavatz JM, Langer R. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev. 1995;16(2- 3):215-233
230. Ogawara KI, Higaki K, Kimura T. Major determinants in hepatic disposition of polystyrene nanospheres: Implication for rational design of particulate drug carriers. Crit Rev Ther Drug Carrier Syst. 2002;19(4- 5):277-306.
231. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and proteinbinding properties. Prog Lipid Res. 2003;42(6):463-478
232. Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2006;307(1):93-102.
233. Vonarbourg A, Passirani C, Saulnier P, Benoit JP. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials. 2006;27(24):4356-4373
234. Moghimi SM, Hunter AC, Murray JC. Long-circulating and targetspecific nanoparticles: theory to practice. Pharmacol Rev. 2001;53(2): 283-318.
235. Gbadamosi JK, Hunter AC, Moghimi SM. PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Lett. 2002;532(3):338-344
236. Meng F, Engbers GHM, Gessner A, Mller RH, Feijen J. Pegylated polystyrene particles as a model system for artificial cells. J Biomed Mater Res A. 2004;70(1):97-106.
237. Claesson PM, Blomberg E, Frberg JC, Nylander T, Arnebrant T. Protein interactions at solid surfaces. Adv Colloid Interface Sci. 1995;57:161-227.
238. Lemarchand C, Gref R, Couvreur P. Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm. 2004;58(2):327-341
239. Jeon SI, Lee JH, Andrade JD, De Gennes PG. Protein-surface interactions in the presence of polyethylene oxide: I. Simplified theory. J Colloid Interface Sci. 1991;142(1):149-158
240. Jeon SI, Andrade JD. Protein-surface interactions in the presence of polyethylene oxide: II. Effect of protein size. J Colloid Interface Sci. 1991;142(1):159-166
241. Vittaz M, Bazile D, Spenlehauer G, Verrecchia T, Veillard M, Puisieux F, Labarre D. Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators. Biomaterials. 1996;17(16):1575-1581
242. Li Y, Pei Y, Zhang X, Gu Z, Zhou Z, Yuan W, Zhou J, Zhu J, Gao X. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release. 2001;71(2):203-211
243. Panagi Z, Beletsi A, Evangelatos G, Livaniou E, Ithakissios DS, Avgoustakis K. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm. 2001;221(1-2):143-152
244. Ameller T, Marsaud R, Legrand P, Gref R, Barratt G, Renoir JM. Polyester-poly(ethylene glycol) nanoparticles loaded with the pure antiestrogen RU 58668: Physicochemical and opsonization properties. Pharm Res. 2003;20(7):1063-1070
245. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Livaniou E, Evangelatos G, Ithakissios DS. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int J Pharm. 2003;259(1-2): 115-127
246. Beletsi A, Panagi Z, Avgoustakis K. Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers. Int J Pharm. 2005;298(1):233-241.
247. Duan Y, Sun X, Gong T, Wang Q, Zhang Z. Preparation of DHAQloaded mPEG-PLGA-mPEG nanoparticles and evaluation of drug release behaviors in vitro/in vivo. J Mater Sci Mater Med. 2006;17(6): 509-516
248. Taek KJ, Yu MO, Shin BC. Preparation of poly(DL-lactide-co-glycolide) nanoparticles by PEG-PPG diblock copolymer. Polymer (Korea). 2003;27(4):370-376
249. Redhead HM, Davis SS, Illum L. Drug delivery in poly(lactide-coglycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: In vitro characterisation and in vivo evaluation. J Control Release. 2001;70(3):353-363
250. Olivier J-C. Drug transport to brain with targeted nanoparticles. NeuroRx. 2005;2(1):108-119
251. Burkersroda F, Gref R, Gpferich A. Erosion of biodegradable block copolymers made of poly(lactic acid) and poly(ethylene glycol). Biomaterials. 1997;18(24):1599-1607
252. Avgoustakis K. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr Drug Deliv. 2004;1(4):321-333
253. Karnik R, Gu F, Basto P, Cannizzaro C, Dean L, Kyei-Manu W, Langer R, Farokhzad OC. Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett. 2008;8(9):2906-2912
254. Moghimi SM. Prolonging the circulation time and modifying the body distribution of intravenously injected polystyrene nanospheres by prior intravenous administration of poloxamine-908. A hepatic-blockade event or manipulation of nanosphere surface in vivo? Biochim Biophys Acta. 1997;1336(1):1-6.
255. Denis-Mize KS, Dupuis M, Singh M, Woo C, Ugozzoli M, OHagan DT, Donnelly JJ, Ott G, McDonald DM. Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell Immunol. 2003;225(1):12-20.
256. Fillafer C, Friedl DS, Wirth M, Gabor F. Fluorescent bionanoprobes to characterize cytoadhesion and cytoinvasion. Small. 2008;4(5):627-633
257. Kang J, Schwendeman SP. Determination of diffusion coefficient of a small hydrophobic probe in poly(lactide-co-glycolide) microparticles by laser scanning confocal microscopy. Macromolecules. 2003;36(4): 1324-1330
258. Eniola AO, Hammer DA. Artificial polymeric cells for targeted drug delivery. J. Control Release. 2003;87(1-3):15-22.
259. Jalón EG, Blanco-Príeto MJ, Ygartua P, Santoyo S. PLGA microparticles: Possible vehicles for topical drug delivery. Int J Pharm. 2001;226(1-2): 181-184
260. Saxena V, Sadoqi M, Shao J. Indocyanine green-loaded biodegradable nanoparticles: preparation, physicochemical characterization and in vitro release. Int J Pharm. 2004;278(2):293-301.
261. Nehilla BJ, Allen PG, Desai TA. Surfactant-free, drug-quantum-dot coloaded poly(lactide-co-glycolide) nanoparticles: Towards multifunctional nanoparticles. ACS Nano. 2008;2(3):538-544
262. Panyam J, Sahoo SK, Prabha S, Bargar T, Labhasetwar V. Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles. Int J Pharm. 2003;262(1-2): 1-11.
263. Weiss B, Schaefer UF, Zapp J, Lamprecht A, Stallmach A, Lehr CM. Nanoparticles made of fluorescence-labelled poly(L-lactide-co-glycolide): preparation, stability, and biocompatibility. J Nanosci Nanotechnol. 2006;6(9-10):3048-3056
264. Tosi G, Rivasi F, Gandolfi F, Costantino L, Vandelli MA, Forni F. Conjugated poly(D,L-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles. Biomaterials. 2005;26(19):4189-4195
265. Chung HJ, Kim HK, Yoon JJ, Park TG. Heparin immobilized porous PLGA microspheres for angiogenic growth factor delivery. Pharm Res. 2006;23(8):1835-1841
266. Mo Y, Lim LY. Mechanistic study of the uptake of wheat germ agglutinin-conjugated PLGA nanoparticles by A549 cells. J Pharm Sci. 2004;93(1):20-28
267. Fillafer C, Ratzinger G, Neumann J, Guttenberg Z, Dissauer S, Lichtscheidl IK, Wirth M, Gabor F, Schneider MF. An acoustically-driven biochip--impact of flow on the cell-association of targeted drug carriers. Lab Chip. 2009;9(19):2782-2788
268. Hawley AE, Illum L, Davis SS. Lymph node localisation of biodegradable nanospheres surface modified with poloxamer and poloxamine block co-polymers. FEBS Lett. 1997;400(3):319-323
269. Delgado A, Soriano I, Snchez E, Oliva M, Évora C. Radiolabelled biodegradable microspheres for lung imaging. Eur J Pharm Biopharm. 2000;50(2):227-236
270. Park YJ, Nah SH, Lee JY, Jeong JM, Chung JK, Lee MC, Yang VC, Lee SJ. Surface-modified poly(lactide-co-glycolide) nanospheres for targeted bone imaging with enhanced labeling and delivery of radioisotope. J Biomed Mater Res A. 2003;67(3):751-760
271. Halder KK, Mandal B, Debnath MC, Bera H, Ghosh LK, Gupta BK. Chloramphenicol-incorporated poly lactide-co-glycolide (PLGA) nanoparticles: Formulation, characterization, technetium-99m labeling and biodistribution studies. J Drug Target. 2008;16(4):311-320
272. Shukla J, Bandopadhyaya GP, Varma IK. 188Rhenium(V)-dimercaptosuccinic acid loaded poly(lactic-co-glycolic)acid microspheres for targeted radiotherapy: production and effectivity. Pharmazie. 2005;60(8):583-587
273. Mo Y, Lim LY. Paclitaxel-loaded PLGA nanoparticles: Potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. J Control Release. 2005;108(2-3):244-262 (Pubitemid 41608658)
274. Le Ray AM, Vert M, Gautier JC, Benoit JP. End-chain radiolabeling and in vitro stability studies of radiolabeled poly(hydroxy acid) nanoparticles. J Pharm Sci. 1994;83(6):845-851
275. Dadachova E, Mirzadeh S. The role of tin in the direct labelling of proteins with rhenium-188. Nucl Med Biol. 1997;24(6):605-608
276. Banerjee T, Singh AK, Sharma RK, Maitra AN. Labeling efficiency and biodistribution of Technetium-99m labeled nanoparticles: Interference by colloidal tin oxide particles. Int J Pharm. 2005;289(1-2): 189-195
277. Fillafer C, Friedl DS, Ilyes AK, Wirth M, Gabor F. Bionanoprobes to study particle-cell interactions. J Nanosci Nanotechnol. 2009;9(5): 3239-3245
278. Pietzonka P, Rothen-Rutishauser B, Langguth P, Wunderli-Allenspach H, Walter E, Merkle HP. Transfer of lipophilic markers from PLGA and polystyrene nanoparticles to Caco-2 monolayers mimics particle uptake. Pharm Res. 2002;19(5):595-601.
279. Cohen S, Yoshioka T, Lucarelli M, Hwang LH, Langer R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm Res. 1991;8(6):713-720
280. Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev. 2005;57(3):391-410.
281. Abbas AO, Donovan MD, Salem AK. Formulating poly(lactideco- glycolide) particles for plasmid DNA delivery. J Pharm Sci. 2008;97(7):2448-2461
282. Ando S, Putnam D, Pack DW, Langer R. PLGA microspheres containing plasmid DNA: Preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J Pharm Sci. 1999;88(1): 126-130
283. Wolf M, Wirth M, Pittner F, Gabor F. Stabilisation and determination of the biological activity of L-asparaginase in poly(D,L-lactide-co-glycolide) nanospheres. Int J Pharm. 2003;256(1-2):141-152
284. Fu K, Pack DW, Klibanov AM, Langer R. Visual evidence of acidic environment within degrading poly(lactic-co- glycolic acid) (PLGA) microspheres. Pharm Res. 2000;17:100-106
285. Ding AG, Schwendeman SP. Acidic microclimate pH distribution in PLGA microspheres monitored by confocal laser scanning microscopy. Pharm Res. 2008;25(9):2041-2052
286. Walter E, Moelling K, Pavlovic J, Merkle HP. Microencapsulation of DNA using poly(DL-lactide-co-glycolide): stability issues and release characteristics. J Control Release. 1999;61(3):361-374
287. Schwendeman SP. Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems. Crit Rev Ther Drug Carrier Syst. 2002;19(1):73-98.
288. Singh M, Kazzaz J, Ugozzoli M, Malyala P, Chesko J, OHagan DT. Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr Drug Deliv. 2006;3(1):115-120
289. Chung YI, Tae G, Hong Yuk S. A facile method to prepare heparinfunctionalized nanoparticles for controlled release of growth factors. Biomaterials. 2006;27(12):2621-2626
290. Singh M, Chesko J, Kazzaz J, Ugozzoli M, Kan E, Srivastava I, OHagan DT. Adsorption of a novel recombinant glycoprotein from HIV (env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not. Pharm Res. 2004;21(12):2148-2152
291. Sapin A, Clavreul A, Garcion E, Benoit JP, Menei P. Evaluation of particulate systems supporting tumor cell fractions in a preventive vaccination against intracranial rat glioma. J Neurosurg. 2006;105(5):745-752
292. Singh M, Ott G, Kazzaz J, Ugozzoli M, Briones M, Donnelly J, OHagan DT. Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm Res. 2001;18(10):1476-1479
293. OHagan D, Singh M, Ugozzoli M, Wild C, Barnett S, Chen M, Schaefer M, Doe B, Otten GR, Ulmer JB. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J Virol. 2001;75(19):9037-9043
294. Singh M, Ugozzoli M, Briones M, Kazzaz J, Soenawan E, OHagan DT. The effect of CTAB concentration in cationic PLG microparticles on DNA adsorption and in vivo performance. Pharm Res. 2003;20(2): 247-251
295. Zhang XQ, Intra J, Salem AK. Comparative study of poly (lactic-coglycolic acid)-poly ethyleneimine-plasmid DNA microparticles prepared using double emulsion methods. J Microencaps. 2008;25:1-12.
296. Briones M, Singh M, Ugozzoli M, Kazzaz J, Klakamp S, Ott G, OHagan D. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery. Pharm Res. 2001;18(5): 709-712 (Pubitemid 32595803)
297. Zhang XQ, Intra J, Salem AK. Conjugation of polyamidoamine dendrimers on biodegradable microparticles for nonviral gene delivery. Bioconjug Chem. 2007;18(6):2068-2076
298. Stivaktakis N, Nikou K, Panagi Z, Beletsi A, Leondiadis L, Avgoustakis K. Immune responses in mice of ?-galactosidase adsorbed or encapsulated in poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres. J Biomed Mater Res A. 2005;73(3):332-338
299. Johansen P, Men Y, Merkle HP, Gander B. Revisiting PLA/PLGA microspheres: An analysis of their potential in parenteral vaccination. Eur J Pharm Biopharm. 2000;50(1):129-146
300. OHagan DT, Singh M, Ulmer JB. Microparticle-based technologies for vaccines. Methods. 2006;40(1):10-19.
301. Johansen P, Martínez Gomez JM, Gander B. Development of synthetic biodegradable microparticulate vaccines: A roller coaster story. Expert Rev Vaccines. 2007;6(4):471-474
302. Capan Y, Woo BH, Gebrekidan S, Ahmed S, DeLuca PP. Preparation and characterization of poly (D,L-lactide-co-glycolide) microspheres for controlled release of poly(L-lysine) complexed plasmid DNA. Pharm Res. 1999;16(4):509-513
303. Howard KA, Alpar HO. The development of polyplex-based DNA vaccines. J Drug Target. 2002;10(2):143-151
304. Zhou X, Liu B, Yu X, Zha X, Zhang X, Wang X, Jin Y, Wu Y, Chen Y, Shan Y, Chen Y, Liu J, Kong W, Shen J. Controlled release of PEI/ DNA complexes from PLGA microspheres as a potent delivery system to enhance immune response to HIV vaccine DNA prime/MVA boost regime. Eur J Pharm Biopharm. 2008;68(3):589-595
305. Howard KA, Li XW, Somavarapu S, Singh J, Green N, Atuah KN, Ozsoy Y, Seymour LW, Alpar HO. Formulation of a microparticle carrier for oral polyplex-based DNA vaccines. Biochim Biophys Acta. 2004;1674(2):149-157
306. OHagan DT, Singh M, Dong C, Ugozzoli M, Berger K, Glazer E, Selby M, Wininger M, Ng P, Crawford K, Paliard X, Coates S, Houghton M. Cationic microparticles are a potent delivery system for a HCV DNA vaccine. Vaccine. 2004;23(5):672-680
307. Mollenkopf HJ, Dietrich G, Fensterle J, Grode L, Diehl KD, Knapp B, Singh M, OHagan DT, Ulmer JB, Kaufmann SHE. Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine. 2004;22(21-22):2690-2695
308. Liman M, Peiser L, Zimmer G, Prpsting M, Naim HY, Rautenschlein S. A genetically engineered prime-boost vaccination strategy for oculonasal delivery with poly(d,l-lactic-co-glycolic acid) microparticles against infection of turkeys with avian Metapneumovirus. Vaccine. 2007;25(46):7914-7926
309. Choudary S, Ravikumar P, Ashok Kumar C, Suryanarayana V, Reddy G. Enhanced immune response of DNA vaccine (VP1-pCDNA) adsorbed on cationic PLG for foot and mouth disease in guinea pigs. Virus Genes. 2008;37(1):81-87
310. He X, Jiang L, Wang F, Xiao Z, Li J, Liu SL, Li D, Ren D, Jin X, Li K, He Y, Shi K, Guo Y, Zhang Y, Sun S. Augmented humoral and cellular immune responses to hepatitis B DNA vaccine adsorbed onto cationic microparticles. J Control Release. 2005;107(2):357-372 (Pubitemid 41316297)
311. Pan C-H, Nair N, Adams RJ, Zink MC, Lee E-Y, Polack FP, Singh M, OHagan DT, Griffin DE. Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticle-adsorbed, alphavirus-based measles virus DNA vaccine in Rhesus macaques. Clin Vaccine Immunol. 2008;15(4):697-706.
312. Verdijk RM, Mutis T, Esendam B, Kamp J, Melief CJM, Brand A, Goulmy E. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol. 1999;163(1):57-61.
313. Cartiera MS, Johnson KM, Rajendran V, Caplan MJ, Saltzman WM. The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials. 2009;30:2790-2798
314. Fillafer C, Wirth M, Gabor F. Stabilizer-induced viscosity alteration biases nanoparticle sizing via dynamic light scattering. Langmuir. 2007;23(17):8699-8702
315. Pean J-M, Venier-Julienne M-C, Boury F, Menei P, Denizot B, Benoit J-P. NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability. J Control Release. 1998;56:175-187
316. Binnig G, Quate CF, Gerber C. Atomic force microscope. Phys Rev Lett. 1986;56(9):930-933
317. Wilkins DJ, Myers PA. Studies on the relationship between the Electrophoretic properties of colloids and their blood clearance and organ distribution in the rat. Br J Exp Pathol. 1966;47(6):568-576
318. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, Hanahan D, McDonald DM. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest. 1998;101:1401-1413
319. Ainslie KM, Lowe RD, Beaudette TT, Petty L, Bachelder EM, Desai TA. Microfabricated devices for enhanced bioadhesive drug delivery: attachment to and small-molecule release through a cell monolayer under flow. Small. 2009;5(24):2857-2863
320. Wheatley MA, Forsberg F, Oum K, Ro R, El-Sherif D. Comparison of in-vitro and in-vivo acoustic response of a novel 50 : 50 PLGA contrast agent. Ultrasonics. 2006;44:360-367